IMDNA develops veterinary infectious-disease research assays for bacterial, viral, fungal, parasitic, vector-borne, antimicrobial-resistance, co-infection, host-response, and molecular-surveillance studies across terrestrial and aquatic animal species.
Research programs can integrate qPCR/RT-qPCR for targeted pathogen nucleic-acid and host-transcript research, ELISA for focused antigen, antibody, or soluble-protein studies, and multiplex bead-based immunoassays for simultaneous cytokine, chemokine, and other species-appropriate protein measurements. Each platform must be validated for the intended species, specimen, analyte, and research purpose.
Livestock, poultry, equine, companion-animal, wildlife, and aquatic-animal research.
Targeted pathogen research, co-infection studies, and emerging-disease assay development.
Support studies at animal–human–environment interfaces without conflating veterinary research with human clinical testing.
Use nucleic-acid, antibody/antigen, and host-response technologies according to the analyte.
Support molecular epidemiology, pathogen evolution, resistance-associated research, and longitudinal studies.
The World Organisation for Animal Health (WOAH) maintains international standards for terrestrial and aquatic animal health and publishes standardized diagnostic approaches in its Codes and Manuals. WOAH's assay-validation framework emphasizes a principle that is central to veterinary assay development: an assay must be fit for its intended purpose and validated for the animal species and specimen in which it will be used.
A method validated in cattle cannot automatically be assumed valid in horses, dogs, poultry, wildlife, fish, or another species. Host biology, pathogen ecology, specimen composition, antibody cross-reactivity, and background microbiota can differ substantially.
Blood, serum, plasma, swabs, milk, feces, tissue, semen, respiratory material, oral fluid, environmental samples, and aquatic specimens can differ in pathogen distribution, inhibitors, matrix effects, and preanalytical stability.
Veterinary pathogens can show substantial strain, genotype, serotype, geographic, and host-associated diversity. Primer/probe inclusivity and exclusivity should be evaluated against contemporary sequence diversity rather than a single reference genome.
Research detection, prevalence studies, experimental challenge models, herd/flock surveillance, antibody research, pathogen characterization, and official disease-status testing are different intended uses and require different evidence, controls, and interpretation.
These categories are designed for research navigation rather than as a complete list of animal diseases. Target selection should follow the species, epidemiological setting, pathogen biology, specimen, and study objective.
Research may address respiratory, enteric, reproductive, mastitis-associated, systemic, vector-borne, and transboundary pathogens.
Support molecular research into endemic, emerging, respiratory, enteric, reproductive, and high-consequence swine pathogens.
Research can address respiratory, enteric, systemic, production-associated, and high-consequence poultry pathogens.
Investigate respiratory, neurologic, reproductive, vector-borne, and systemic infectious-disease biology in equine populations.
Support pathogen and immune-response studies relevant to small-ruminant respiratory, enteric, reproductive, vector-borne, and transboundary disease.
Targeted research for canine and feline viral, bacterial, vector-borne, parasitic, respiratory, gastrointestinal, and systemic infections.
Wildlife can act as host, reservoir, sentinel, or affected population. WOAH maintains wildlife-health resources and recognizes the need for species-appropriate validation in wildlife diagnostics.
WOAH maintains a separate Aquatic Animal Health Code and Diagnostic Manual because fish, crustacean, mollusc, and amphibian disease systems require dedicated sampling and validation frameworks.
Pathogen presence is only one biological layer. Veterinary research may integrate pathogen detection with host response, antimicrobial resistance, molecular epidemiology, vaccination status, or longitudinal outcome studies.
Targeted detection of bacterial, viral, fungal, parasitic, or vector-borne nucleic acids using species- and specimen-validated workflows.
Quantitative or relative research across experimental infection, treatment, shedding, transmission, or longitudinal studies when appropriate standards support interpretation.
Investigate multiple pathogens within respiratory, enteric, reproductive, systemic, or other syndromic research models.
Study cytokine, chemokine, interferon, innate, adaptive, inflammatory, and tissue-response pathways using species-appropriate assays and reagents.
Use ELISA or other immunoassays to study humoral responses, seroconversion, antigen exposure, vaccine responses, or selected pathogen proteins.
Investigate selected bacterial, fungal, viral, or parasitic resistance determinants while distinguishing molecular genotype from phenotypic susceptibility.
Support prevalence, strain circulation, outbreak research, geographic distribution, seasonality, and transmission studies.
Compare antibody, host-response, or pathogen-associated measurements across vaccinated, unvaccinated, challenged, or longitudinal groups.
Study pathogens and AMR at animal–human–environment interfaces while maintaining species-specific assay validation and appropriate biosafety/regulatory frameworks.
Research pathogens transmitted by ticks, mosquitoes, biting flies, or other vectors in host animals and, where appropriate, vector specimens.
Evaluate oral fluids, pooled swabs, milk, water, litter, environmental surfaces, or other population-level specimens after matrix-specific validation.
Design research assays around new sequence information, emerging hosts, novel variants, or evolving epidemiological questions with ongoing re-evaluation of target conservation.
The analytical platform should follow the analyte and intended use. Pathogen nucleic acid, antibody, antigen, host transcript, and cytokine concentration represent different measurements and require independent validation.
Best suited for: targeted DNA/RNA pathogen research and focused host-transcript studies.
Development principle: use WOAH species/specimen fit-for-purpose validation concepts together with MIQE 2.0 principles for assay specificity, controls, amplification performance, analytical range, and transparent reporting.
Best suited for: focused antibody, antigen, or soluble-protein research when validated species-compatible reagents are available.
Development principle: evaluate species specificity, matrix effects, cross-reactivity, working range, precision, cutoff strategy where relevant, parallelism/recovery, stability, and vaccination/exposure context.
Best suited for: simultaneous measurement of multiple host-response proteins when species-specific antibody pairs and validated standards are available.
Development principle: species cross-reactivity must be demonstrated. Each analyte requires multiplex-context evaluation for sensitivity, matrix effects, cross-talk, parallelism, standard behavior, lot effects, and inter-run precision.
These examples illustrate assay architecture rather than fixed diagnostic panels. Disease names or example pathogens should be selected only when relevant to the species, geography, specimen, and intended research purpose.
One of the most important differences between general molecular research and veterinary infectious-disease research is the diversity of hosts, specimens, vaccination programs, production systems, and pathogen ecologies.
| Measurement | What It Can Support | Important Limitation |
|---|---|---|
| Pathogen qPCR / RT-qPCR | Research detection of a targeted pathogen nucleic acid in a validated specimen. | Detection does not automatically prove viability, clinical causation, infectiousness, or disease severity. |
| Cq / Ct value | Can support relative or quantitative research when assay efficiency, standards, specimen input, and workflow are controlled. | Cq values should not be interpreted as directly comparable pathogen loads across assays, species, specimens, or laboratories without validation. |
| Antibody ELISA | Research seroconversion, exposure, vaccine response, or longitudinal humoral immunity. | Antibodies may reflect prior exposure or vaccination and do not necessarily indicate active infection. |
| Antigen ELISA | Research detection of a selected pathogen-associated protein. | Performance depends on antigen abundance, epitope conservation, specimen matrix, and antibody specificity. |
| Host cytokine panel | Study inflammatory or immune-response biology. | Species-specific reagents and standards are essential; cytokine responses are generally not pathogen-specific. |
| AMR gene detection | Investigate selected resistance determinants. | Genotype may not reproduce the full phenotypic susceptibility profile and must be interpreted in organism-specific context. |
WOAH's validation framework describes assay validation as determining fitness for an intended purpose. For veterinary infectious-disease research, species, specimen, epidemiological context, and target diversity should be built into development from the beginning.
| Stage | Best-Practice Approach | Scientific Rationale |
|---|---|---|
| 1. Define intended research use | Specify animal species, age/production class, disease model, pathogen/analyte, specimen, geography, vaccination status, comparator, and endpoint. | Determines the validation evidence and controls required. |
| 2. Define pathogen diversity | Evaluate contemporary sequence diversity, strains, serotypes/genotypes, host-associated lineages, and geographic variants. | Veterinary pathogen diversity can cause false negatives if target sites are not sufficiently conserved. |
| 3. Design inclusivity & exclusivity strategy | Use in-silico analysis plus empirical testing against intended targets, related organisms, host genomes, commensals, and relevant matrices. | A bovine respiratory qPCR meta-analysis found that many published veterinary primer/probe sets had questionable in-silico specificity, reinforcing the need for rigorous design. |
| 4. Match technology to analyte | Use qPCR/RT-qPCR for nucleic acid, ELISA for focused antibody/antigen/protein research, and multiplex immunoassay for species-compatible multianalyte protein profiling. | These platforms answer different biological questions. |
| 5. Validate analytical performance | Evaluate analytical sensitivity, specificity, repeatability, reproducibility, range, inhibition, matrix effects, robustness, and multiplex compatibility as appropriate. | WOAH states that validation should estimate relevant analytical and diagnostic performance characteristics for the intended purpose. |
| 6. Use fit-for-purpose controls | Include extraction/process, inhibition, negative, positive, reference, and platform-specific QC materials as appropriate. | Controls should challenge the actual failure modes of the assay and specimen. |
| 7. Verify in the intended species & specimen | Test characterized samples from the target species and specimen type rather than relying only on synthetic or heterologous materials. | WOAH explicitly states that assays should be validated for the species and specimen in which they will be used. |
| 8. Maintain ongoing fitness | Monitor sequence evolution, reagent lots, instrument performance, emerging variants, epidemiological changes, and assay drift. | An assay that was fit for purpose at development may require re-evaluation as pathogens and use conditions change. |
Veterinary infectious-disease research requires careful separation of pathogen detection, disease causation, official disease status, host response, exposure history, and population-level epidemiology.
WOAH publishes international diagnostic standards, and USDA APHIS uses NVSL, NAHLN, and approved laboratories for specified animal-disease testing in the United States. Some high-consequence diseases require testing through official or authorized laboratory networks.
Therefore: IMDNA positions these assays for research use—pathogen biology, molecular epidemiology, host response, surveillance research, assay development, and translational veterinary studies—not as official disease-status, trade-certification, or regulatory diagnostic tests.
A rigorous veterinary workflow connects species, pathogen biology, specimen selection, analytical technology, assay validation, biological verification, and ongoing surveillance of assay fitness.
Veterinary assay quality requires both platform-specific analytical controls and species-specific biological validation.
Document host species, age/production group, vaccination status, specimen type, collection method, transport, storage, pooling, and preanalytical conditions.
Use current sequence data, inclusivity/exclusivity analysis, and empirical testing against related organisms, host DNA/RNA, and relevant microbiota.
Evaluate efficiency, analytical range, sensitivity, inhibition, specificity, precision, multiplex competition, and instrument/reagent robustness.
Evaluate species compatibility, antigen/antibody specificity, matrix effects, precision, cutoff strategy where relevant, vaccination effects, and cross-reactivity.
Confirm species-reactive antibody pairs and analyte standards, then evaluate sensitivity, parallelism, matrix effects, cross-talk, lot effects, and inter-run variability.
Use fit-for-purpose positive and negative materials, proficiency/QC approaches, and documented monitoring of lot, instrument, and assay performance.
Veterinary infectious-disease research rarely fits one universal panel. IMDNA can develop integrated research solutions using qPCR/RT-qPCR, ELISA, multiplex bead-based immunoassays, or a scientifically justified combination of these technologies.
Whether your work focuses on cattle, swine, poultry, equine, sheep and goats, companion animals, wildlife, aquaculture, zoonotic disease, vector-borne infection, antimicrobial resistance, co-infection, host response, molecular epidemiology, vaccination, emerging pathogens, or surveillance research, IMDNA can develop a focused molecular and protein research strategy around the species, pathogen, specimen, and biological question that matter to your study.